Literature DB >> 14566721

Chondrosarcoma of the bones of the feet.

Sanjeev Patil1, M V Chandu de Silva, Jim Crossan, Robin Reid.   

Abstract

Twelve chondrosarcomas of the bones of the feet from 11 patients in the Scottish Bone Tumor Registry were reviewed. One patient with diaphyseal aclasis (osteochondromatosis) developed 2 chondrosarcomas. The mean age of patients was 52.3 years (range, 17 to 83 years). Men were predominantly affected. Four tumors affected the tarsal bones; the rest involved the short tubular bones. The usual clinical presentation was a painful, progressively enlarging swelling. Radiologically, most showed some bone expansion, cortical destruction with indistinct margins, and soft-tissue extension. Histologically, the majority were middle-grade tumors. Treatment included curettage or local excision for 4 tumors and amputation or ray resection for 8 tumors. Follow-up varied from 6 months to 18 years (average, 5.8 years). Local recurrence after surgery was seen in 3 patients. All 3 died because of metastases to the lungs or brain.

Entities:  

Mesh:

Year:  2003        PMID: 14566721     DOI: 10.1016/s1067-2516(03)00306-5

Source DB:  PubMed          Journal:  J Foot Ankle Surg        ISSN: 1067-2516            Impact factor:   1.286


  4 in total

Review 1.  The imaging of cartilaginous bone tumours. II. Chondrosarcoma.

Authors:  H Douis; A Saifuddin
Journal:  Skeletal Radiol       Date:  2012-10-04       Impact factor: 2.199

2.  [Tumors of the foot: diagnostics and therapy].

Authors:  A Toepfer; U Lenze; B M Holzapfel; H Rechl; R von Eisenhart-Rothe; H Gollwitzer
Journal:  Orthopade       Date:  2012-07       Impact factor: 1.087

3.  Multiple hereditary osteochondromatosis: a case report.

Authors:  Cigdem Küçükesmen; Bugra Ozen; Mustafa Akçam
Journal:  Eur J Dent       Date:  2007-07

Review 4.  [Foot and ankle tumours : Part II: Malignant bone tumours and soft tissue tumours of the foot with differential diagnostic hints].

Authors:  T Grieser
Journal:  Radiologe       Date:  2018-05       Impact factor: 0.635

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.